Abstract
This chapter provides an overview of the evidence of oxidative stress and compensatory responses in response to arsenic exposure in diverse in vitro models of cardiovascular diseases, type 2 diabetes mellitus and neurodegenerative disorders. The studies described here are recent approaches related to (1) the presence of oxidative and nitrosative damage; (2) the activation of novel and sensitive oxidative stress targets providing an environment conducive to the onset and progression of these diseases. We emphasize the need for further studies exploring the usefulness of the novel oxidative and nitrosative stress targets as biological markers of As toxicity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer’s disease
- AMPK:
-
AMP-activated kinase
- AP-1:
-
Activator protein-1
- aP2:
-
Adipocyte-selective fatty acid-binding protein
- As:
-
Arsenic
- C/EBPα:
-
CCAAT-enhancer binding protein α
- COX-2:
-
Cyclooxygenase-2
- CVDs:
-
Cardiovascular diseases
- DMAIII:
-
Dimethylarsinous acid
- DMAsIIIO:
-
Iododimethylarsine
- DMAV:
-
Dimethylarsinic acid
- ERK:
-
Extracellular signal regulated kinase
- GLUT-4:
-
Glucose transporter 4
- GSH:
-
Glutathione
- HUVEC:
-
Human umbilical vein endothelial cells
- IL-6:
-
Interleukin-6
- JNK:
-
c-Jun N-terminal kinase
- MAPK:
-
Mitogen-activated protein kinases
- MAPT:
-
Microtubule-associated protein-tau
- MAsIIIO:
-
Methylarsine oxide
- MCP-1:
-
Monocyte chemoattractant protein-1
- MMAIII:
-
Monomethylarsonous acid
- MMAV:
-
Monomethylarsonic acid
- NEF3:
-
Neurofilament-medium
- NEFH:
-
Neurofilament-heavy
- NEFL:
-
Neurofilament-light
- NFH:
-
Neurofilament high molecular weight subunit
- NFTs:
-
Neurofibrillary tangles
- NF-κB:
-
Nuclear factor-κB
- NO:
-
Nitric oxide
- NOS:
-
Nitric oxide synthases
- Nrf2:
-
NF-E2-related factor 2
- PDK-1:
-
3-Phosphoinositide-dependent kinase-1
- PG:
-
Proteoglycans
- PI-3K:
-
Phosphatidylinositol 3-kinase
- PIP3:
-
Phosphatidylinositol-3,4,5-triphosphate
- PKB/Akt:
-
Protein kinase B
- PPARγ:
-
Peroxisome proliferative-activated receptor γ
- PTEN:
-
Phosphatase and tensin homolog deleted on chromosome ten
- RNS:
-
Reactive nitrogen species
- ROS:
-
Reactive oxygen species
- S1P1 :
-
Type 1 sphingosine-1-phosphate
- SAPKs:
-
Stress-activated protein kinases
- T2DM:
-
Diabetes mellitus type 2
- TAT:
-
Tyrosine aminotransferase
- TNF-α:
-
Tumor necrosis factor-α
- VE-cadherin:
-
Vascular endothelial cadherin
- VSMCs:
-
Vascular smooth muscle cells
References
Valko, M., et al., Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact, 2006. 160(1): p. 1–40.
Valko, M., et al., Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem, 2004. 266(1-2): p. 37–56.
Inoue, M., et al., Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem, 2003. 10(23): p. 2495–505.
Gurr, J.R., et al., Nitric oxide production by arsenite. Mutat Res, 2003. 533(1-2): p. 173–82.
Liu, S.X., et al., Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci U S A, 2001. 98(4): p. 1643–8.
Alderton, W.K., C.E. Cooper, and R.G. Knowles, Nitric oxide synthases: structure, function and inhibition. Biochem J, 2001. 357(Pt 3): p. 593–615.
Bergendi, L., et al., Chemistry, physiology and pathology of free radicals. Life Sci, 1999. 65(18-19): p. 1865–74.
Kawashima, S. and M. Yokoyama, Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol, 2004. 24(6): p. 998–1005.
Balakumar, P., T. Kaur, and M. Singh, Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology, 2008. 245(1-2): p. 49–64.
Kitchin, K.T. and S. Ahmad, Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol Lett, 2003. 137(1-2): p. 3–13.
Halliwell, B. and M. Whiteman, Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol, 2004. 142(2): p. 231–55.
Kligerman, A.D. and A.H. Tennant, Insights into the carcinogenic mode of action of arsenic. Toxicol Appl Pharmacol, 2007. 222(3): p. 281–8.
Diaz-Villasenor, A., et al., Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol, 2007. 225(2): p. 123–33.
Navas-Acien, A., et al., Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol, 2005. 162(11): p. 1037–49.
Prozialeck, W.C., et al., The vascular system as a target of metal toxicity. Toxicol Sci, 2008. 102(2): p. 207–18.
Schmuck, E.M., et al., Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet Genomics, 2005. 15(7): p. 493–501.
Vahidnia, A., G.B. van der Voet, and F.A. de Wolff, Arsenic neurotoxicity--a review. Hum Exp Toxicol, 2007. 26(10): p. 823–32.
Wang, C.H., et al., Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation, 2002. 105(15): p. 1804–9.
Hsueh, Y.M., et al., Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis, 1998. 141(2): p. 249–57.
Chiou, H.Y., et al., Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke, 1997. 28(9): p. 1717–23.
Chen, C.J., et al., Increased prevalence of hypertension and long-term arsenic exposure. Hypertension, 1995. 25(1): p. 53–60.
Lee, M.Y. and K.K. Griendling, Redox signaling, vascular function, and hypertension. Antioxid Redox Signal, 2008. 10(6): p. 1045–59.
Lyle, A.N. and K.K. Griendling, Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda), 2006. 21: p. 269–80.
Garcia-Palmieri, M.R., The endothelium in health and in cardiovascular disease. P R Health Sci J, 1997. 16(2): p. 136–41.
Schalkwijk, C.G. and C.D. Stehouwer, Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond), 2005. 109(2): p. 143–59.
Chatterjee, A., S.M. Black, and J.D. Catravas, Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol, 2008. 49(4-6): p. 134–40.
Davignon, J. and P. Ganz, Role of endothelial dysfunction in atherosclerosis. Circulation, 2004. 109(23 Suppl 1): p. III27–32.
Savoia, C. and E.L. Schiffrin, Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond), 2007. 112(7): p. 375–84.
Cai, H. and D.G. Harrison, Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res, 2000. 87(10): p. 840–4.
Libby, P., Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol, 2000. 23 Suppl 6: p. VI-3–7.
Simeonova, P.P. and M.I. Luster, Arsenic and atherosclerosis. Toxicol Appl Pharmacol, 2004. 198(3): p. 444–9.
Willerson, J.T. and P.M. Ridker, Inflammation as a cardiovascular risk factor. Circulation, 2004. 109(21 Suppl 1): p. II2–10.
Bunderson, M., J.D. Coffin, and H.D. Beall, Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol, 2002. 184(1): p. 11–8.
Tsou, T.C., et al., Arsenite enhances tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1. Toxicol Appl Pharmacol, 2005. 209(1): p. 10–8.
Jindal, S., M. Singh, and P. Balakumar, Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol, 2008. 128(3): p. 383–91.
Nuntharatanapong, N., et al., EGF receptor-dependent JNK activation is involved in arsenite-induced p21Cip1/Waf1 upregulation and endothelial apoptosis. Am J Physiol Heart Circ Physiol, 2005. 289(1): p. H99–H107.
Balakumar, P. and J. Kaur, Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol, 2009. 9(4): p. 169–76.
Mertens, A. and P. Holvoet, Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J, 2001. 15(12): p. 2073–84.
Wang, C.H., et al., A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol, 2007. 222(3): p. 315–26.
Tseng, C.H., Cardiovascular disease in arsenic-exposed subjects living in the arseniasis-hyperendemic areas in Taiwan. Atherosclerosis, 2008. 199(1): p. 12–8.
Simeonova, P.P., et al., Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ Health Perspect, 2003. 111(14): p. 1744–8.
Bunderson, M., et al., Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol, 2004. 201(1): p. 32–9.
Barchowsky, A., et al., Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med, 1999. 27(11-12): p. 1405–12.
Lynn, S., et al., NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res, 2000. 86(5): p. 514–9.
Smith, K.R., L.R. Klei, and A. Barchowsky, Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am J Physiol Lung Cell Mol Physiol, 2001. 280(3): p. L442–9.
Straub, A.C., et al., Arsenic requires sphingosine-1-phosphate type 1 receptors to induce angiogenic genes and endothelial cell remodeling. Am J Pathol, 2009. 174(5): p. 1949–58.
Schieffer, B., et al., Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation, 2004. 110(22): p. 3493–500.
Griendling, K.K., et al., Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol, 2000. 20(10): p. 2175–83.
Irani, K., Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res, 2000. 87(3): p. 179–83.
Wu, M.M., et al., Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect, 2003. 111(11): p. 1429–38.
Lee, P.C., I.C. Ho, and T.C. Lee, Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci, 2005. 85(1): p. 541–50.
Pereira, F.E., J.D. Coffin, and H.D. Beall, Activation of protein kinase C and disruption of endothelial monolayer integrity by sodium arsenite--Potential mechanism in the development of atherosclerosis. Toxicol Appl Pharmacol, 2007. 220(2): p. 164–77.
Fujiwara, Y., et al., Arsenite but not arsenate inhibits general proteoglycan synthesis in cultured arterial smooth muscle cells. J Toxicol Sci, 2008. 33(4): p. 487–92.
Klei, L.R. and A. Barchowsky, Positive signaling interactions between arsenic and ethanol for angiogenic gene induction in human microvascular endothelial cells. Toxicol Sci, 2008. 102(2): p. 319–27.
Bae, O.N., et al., Arsenite-enhanced procoagulant activity through phosphatidylserine exposure in platelets. Chem Res Toxicol, 2007. 20(12): p. 1760–8.
Bae, O.N., et al., Trivalent methylated arsenical-induced phosphatidylserine exposure and apoptosis in platelets may lead to increased thrombus formation. Toxicol Appl Pharmacol, 2009. 239(2): p. 144–53.
Sanders, K.M., Invited review: mechanisms of calcium handling in smooth muscles. J Appl Physiol, 2001. 91(3): p. 1438–49.
Lee, M.Y., et al., Inorganic arsenite potentiates vasoconstriction through calcium sensitization in vascular smooth muscle. Environ Health Perspect, 2005. 113(10): p. 1330–5.
Bilszta, J.L., G.J. Dusting, and F. Jiang, Arsenite increases vasoconstrictor reactivity in rat blood vessels: role of endothelial nitric oxide function. Int J Toxicol, 2006. 25(4): p. 303–10.
Bae, O.N., et al., Vascular smooth muscle dysfunction induced by monomethylarsonous acid (MMA III): a contributing factor to arsenic-associated cardiovascular diseases. Environ Res, 2008. 108(3): p. 300–8.
Pysher, M.D., Q.M. Chen, and R.R. Vaillancourt, Arsenic alters vascular smooth muscle cell focal adhesion complexes leading to activation of FAK-src mediated pathways. Toxicol Appl Pharmacol, 2008. 231(2): p. 135–41.
Wild, S., et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004. 27(5): p. 1047–53.
Longnecker, M.P. and J.L. Daniels, Environmental contaminants as etiologic factors for diabetes. Environ Health Perspect, 2001. 109 Suppl 6: p. 871–6.
Navas-Acien, A., et al., Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect, 2006. 114(5): p. 641–8.
Nabi, A.H., M.M. Rahman, and L.N. Islam, Evaluation of biochemical changes in chronic arsenic poisoning among Bangladeshi patients. Int J Environ Res Public Health, 2005. 2(3-4): p. 385–93.
Chiu, H.F., et al., Does arsenic exposure increase the risk for diabetes mellitus? J Occup Environ Med, 2006. 48(1): p. 63–7.
Coronado-Gonzalez, J.A., et al., Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res, 2007. 104(3): p. 383–9.
Meliker, J.R., et al., Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health, 2007. 6: p. 4.
Navas-Acien, A., et al., Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA, 2008. 300(7): p. 814–22.
Tseng, C.H., The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol, 2004. 197(2): p. 67–83.
Fridlyand, L.E. and L.H. Philipson, Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes, 2004. 53(8): p. 1942–8.
Maiese, K., Z.Z. Chong, and Y.C. Shang, Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem, 2007. 14(16): p. 1729–38.
Pi, J., et al., Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes, 2007. 56(7): p. 1783–91.
Pi, J., et al., Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology, 2009. 150(7): p. 3040–8.
Houstis, N., E.D. Rosen, and E.S. Lander, Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 2006. 440(7086): p. 944–8.
Tiedge, M., et al., Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes, 1997. 46(11): p. 1733–42.
Matsumura, N., et al., Study on free radicals and pancreatic fibrosis--pancreatic fibrosis induced by repeated injections of superoxide dismutase inhibitor. Pancreas, 2001. 22(1): p. 53–7.
Macfarlane, W.M., et al., Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic beta-cells. J Biol Chem, 1999. 274(2): p. 1011–6.
Wauson, E.M., A.S. Langan, and R.L. Vorce, Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol Sci, 2002. 65(2): p. 211–9.
Bazuine, M., et al., Arsenite stimulated glucose transport in 3T3-L1 adipocytes involves both Glut4 translocation and p38 MAPK activity. Eur J Biochem, 2003. 270(19): p. 3891–903.
Pi, J., et al., Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp Cell Res, 2003. 290(2): p. 234–45.
Bodwell, J.E., L.A. Kingsley, and J.W. Hamilton, Arsenic at very low concentrations alters glucocorticoid receptor (GR)-mediated gene activation but not GR-mediated gene repression: complex dose-response effects are closely correlated with levels of activated GR and require a functional GR DNA binding domain. Chem Res Toxicol, 2004. 17(8): p. 1064–76.
Hamilton, J.W., et al., Molecular basis for effects of carcinogenic heavy metals on inducible gene expression. Environ Health Perspect, 1998. 106 Suppl 4: p. 1005–15.
Walton, F.S., et al., Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. Toxicol Appl Pharmacol, 2004. 198(3): p. 424–33.
Paul, D.S., et al., Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid. Environ Health Perspect, 2007. 115(5): p. 734–42.
Paul, D.S., et al., Examination of the effects of arsenic on glucose homeostasis in cell culture and animal studies: development of a mouse model for arsenic-induced diabetes. Toxicol Appl Pharmacol, 2007. 222(3): p. 305–14.
Izquierdo-Vega, J.A., et al., Diabetogenic effects and pancreatic oxidative damage in rats subchronically exposed to arsenite. Toxicol Lett, 2006. 160(2): p. 135–42.
Diaz-Villasenor, A., et al., Sodium arsenite impairs insulin secretion and transcription in pancreatic beta-cells. Toxicol Appl Pharmacol, 2006. 214(1): p. 30–4.
Fu, J., et al., Low Level Arsenic Impairs Glucose-Stimulated Insulin Secretion in Pancreatic Beta-Cells: Involvement of Cellular Adaptive Response to Oxidative Stress. Environ Health Perspect, 2010.
Grandjean, P. and P.J. Landrigan, Developmental neurotoxicity of industrial chemicals. Lancet, 2006. 368(9553): p. 2167–78.
Rosado, J.L., et al., Arsenic exposure and cognitive performance in Mexican schoolchildren. Environ Health Perspect, 2007. 115(9): p. 1371–5.
Trojanowski, J.Q. and V.M. Lee, “Fatal attractions” of proteins. A comprehensive hypothetical mechanism underlying Alzheimer’s disease and other neurodegenerative disorders. Ann N Y Acad Sci, 2000. 924: p. 62–7.
Giasson, B.I., et al., The environmental toxin arsenite induces tau hyperphosphorylation. Biochemistry, 2002. 41(51): p. 15376–87.
Su, B., et al., Oxidative stress signaling in Alzheimer’s disease. Curr Alzheimer Res, 2008. 5(6): p. 525–32.
Liu, Y., et al., Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic Biol Med, 1996. 21(6): p. 771–81.
Zarazua, S., et al., Decreased nitric oxide production in the rat brain after chronic arsenic exposure. Neurochem Res, 2006. 31(8): p. 1069–77.
Das, J., et al., Arsenic-induced oxidative cerebral disorders: protection by taurine. Drug Chem Toxicol, 2009. 32(2): p. 93–102.
Namgung, U. and Z. Xia, Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase. J Neurosci, 2000. 20(17): p. 6442–51.
Namgung, U. and Z. Xia, Arsenic induces apoptosis in rat cerebellar neurons via activation of JNK3 and p38 MAP kinases. Toxicol Appl Pharmacol, 2001. 174(2): p. 130–8.
Dhar, P., N. Mohari, and R.D. Mehra, Preliminary morphological and morphometric study of rat cerebellum following sodium arsenite exposure during rapid brain growth (RBG) period. Toxicology, 2007. 234(1-2): p. 10–20.
Giasson, B.I. and W.E. Mushynski, Aberrant stress-induced phosphorylation of perikaryal neurofilaments. J Biol Chem, 1996. 271(48): p. 30404–9.
Vahidnia, A., et al., Arsenic metabolites affect expression of the neurofilament and tau genes: an in-vitro study into the mechanism of arsenic neurotoxicity. Toxicol In Vitro, 2007. 21(6): p. 1104–12.
Vahidnia, A., et al., Mechanism of arsenic-induced neurotoxicity may be explained through cleavage of p35 to p25 by calpain. Toxicol In Vitro, 2008. 22(3): p. 682–7.
Rios, R., et al., Decreased nitric oxide markers and morphological changes in the brain of arsenic-exposed rats. Toxicology, 2009. 261(1-2): p. 68–75.
Wang, X., et al., Arsenic Inhibits Neurite Outgrowth by Inhibiting LKB1-AMPK Signaling Pathway. Environ Health Perspect, 2010. doi: 10.1289/ehp.0901510
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ruíz-Ramos, R., Ostrosky-Wegman, P., Cebrián, M.E. (2011). Arsenic-Induced Oxidative Stress: Evidence on In Vitro Models of Cardiovascular, Diabetes Mellitus Type 2 and Neurodegenerative Disorders. In: Basu, S., Wiklund, L. (eds) Studies on Experimental Models. Oxidative Stress in Applied Basic Research and Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-956-7_33
Download citation
DOI: https://doi.org/10.1007/978-1-60761-956-7_33
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-955-0
Online ISBN: 978-1-60761-956-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)